Deucravacitinib-TNF Combination Therapy for Difficult-to-Control Psoriatic Disease
Status:
NOT_YET_RECRUITING
Trial end date:
2027-12-15
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the effectiveness of adding deucravacitinib to the participant's current Psoriatic Arthritis (PsA) treatment to see if it improves their symptoms and quality of life.
This study is exploring a new treatment approach that may help improve control of psoriatic disease by targeting different parts of the disease process. By combining therapies that work together, the goal is to offer better symptom relief with fewer or more manageable side effects than some current treatments.